NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
April 17, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced...
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
March 05, 2024 16:05 ET
|
NeuroPace, Inc.
-- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 -- -- Revenue increased to $65.4 million in 2023, a 44% increase over 2022 -- -- Provides full-year 2024 revenue...
NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
December 21, 2023 07:07 ET
|
NeuroPace, Inc.
NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy Neuromodulation therapy is not currently...
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023 16:30 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
December 04, 2023 17:07 ET
|
NeuroPace, Inc.
First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data...
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
December 01, 2023 08:00 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023 08:00 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
November 06, 2023 16:03 ET
|
NeuroPace, Inc.
Third quarter 2023 revenue of $16.4 million, an increase of 47% year-over-year Full-year revenue guidance increased to $62.5-$63.5 million, up from $59-$61 million Cash burn reduced to $2.2 million...
NeuroPace Announces RNS System Enhancements Designed to Streamline Care
October 17, 2023 16:05 ET
|
NeuroPace, Inc.
- Upgraded nSight Platform Improves Clinicians’ Ability to Track, Review and Evaluate Patient Data - - ‘Simple Set Programming’ Enables Complete Programming Set Transfer Directly to RNS Tablet - -...
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
October 16, 2023 17:01 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...